Healthcare Industry News: Boston Scientific
News Release - April 19, 2010
Boston Scientific's Urology and Women's Health Division Strengthens Marketing Alliance With Bladder Health NetworkExclusive agreement promotes access to testing solutions for female urinary incontinence
NATICK, Mass., April 19 (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE:BSX ) today announced that it has entered into a four-year exclusive marketing agreement with Bladder Health Network (BHN), a privately held company offering advanced testing solutions for urinary incontinence. BHN offers an integrated diagnostic solutions platform that combines software, staffing, equipment, supplies and results analysis, providing physicians and their patients with greater access to testing, interpretation and treatment options for urinary incontinence and other problems related to the urinary system.
As part of the agreement, Boston Scientific's Urology and Women's Health Division will market BHN's female urodynamic testing solutions to U.S. health care providers. Urodynamics testing employs sophisticated equipment to measure the amount of pressure experienced by the bladder and urethra in order to evaluate the function and efficiency of a patient's urinary system.
"The agreement with BHN allows Boston Scientific to introduce health care providers to a female continence care platform that offers professional testing and results interpretation," said John Pedersen, Senior Vice President and President of Boston Scientific's Urology and Women's Health Division. "This agreement demonstrates Boston Scientific's continuing commitment to the women's health community."
"With Boston Scientific we've found an industry leader who shares our vision of improving the quality of continence care," said John Spivey, President and Chief Executive Officer of BHN. "This agreement enhances our ability to deliver compelling solutions to the market, enhance patient care and create better efficiencies for physicians."
It is estimated that urinary incontinence affects one out of four women in the United States and can have a significant impact on quality of life. Symptoms include leaking urine, difficulty emptying the bladder, frequent urination, recurrent infections and loss of bladder support.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
About Bladder Health Network (BHN)
BHN provides software, services, and products to assist physicians in continence diagnostics and other pelvic health therapy solutions. For more information, please visit: www.bladderhealthnetwork.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding patient care, product performance, our strategic alliances, our growth strategy, and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
Source: Boston Scientific
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsNew Four-Year Data Demonstrate Rezūm(TM) Water Vapor Therapy Offers Significant Durable Improvement of Benign Prostatic Hyperplasia Symptoms
Neovasc Announces Dismissal of Claim brought by Edwards Lifesciences
VICI VENOUS STENT(R) System Demonstrates Positive Clinical Outcomes in Patients with Deep Venous Blockages